Patents by Inventor Hitt Jyoti SHARMA

Hitt Jyoti SHARMA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
    Patent number: 11179453
    Abstract: An immunogenic composition comprising of Diphtheria toxoid antigen (D), tetanus toxoid (T) antigen, Hepatitis B surface antigen (HBsAg), inactivated whole-cell B. pertussis (wP) antigen, Haemophilus influenzae type B (Hib) capsular saccharide conjugated to a carrier protein, Inactivated Polio Virus (IPV) antigen and additionally one or more antigens and the method of preparing the same. A fully liquid combination vaccine, showing improved immunogenicity, reduced reactogenicity and improved stability. Improved methods of formaldehyde inactivation, improved adsorption profile of Diphtheria toxoid antigen (D), tetanus toxoid (T) antigen and Hepatitis B (HepB) surface antigen adsorbed individually onto aluminium phosphate adjuvant, minimum total aluminum content (Al3+) and optimized concentration of 2-phenoxyethanol (2-PE) as preservative.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: November 23, 2021
    Assignee: SERUM INSTITUTE OF INDIA PVT LTD
    Inventors: Rakesh Kumar, Inder Jit Sharma, Anil Vyankatrao Shitole, Manohar Doddapaneni, Hitt Jyoti Sharma
  • AN IMMUNOGENIC COMPOSITION HAVING IMPROVED STABILITY, ENHANCED IMMUNOGENICITY AND REDUCED REACTOGENICITY AND PROCESS FOR PREPARATION THEREOF
    Publication number: 20200206331
    Abstract: An immunogenic composition comprising of Diphtheria toxoid antigen (D), tetanus toxoid (T) antigen, Hepatitis B surface antigen (HBsAg), inactivated whole-cell B. pertussis (wP) antigen, Haemophilus influenzae type B (Hib) capsular saccharide conjugated to a carrier protein, Inactivated Polio Virus (IPV) antigen and additionally one or more antigens and the method of preparing the same. A fully liquid combination vaccine, showing improved immunogenicity, reduced reactogenicity and improved stability. Improved methods of formaldehyde inactivation, improved adsorption profile of Diphtheria toxoid antigen (D), tetanus toxoid (T) antigen and Hepatitis B (HepB) surface antigen adsorbed individually onto aluminium phosphate adjuvant, minimum total aluminum content (Al3+) and optimized concentration of 2-phenoxyethanol (2-PE) as preservative.
    Type: Application
    Filed: July 13, 2018
    Publication date: July 2, 2020
    Inventors: Rakesh KUMAR, Inder Jit SHARMA, Anil Vyankatrao SHITOLE, Manohar DODDAPANENI, Hitt Jyoti SHARMA